The use of the peroxisome proliferator-activated receptors γ agonist rosiglitazone to treat airway hyperreactivity.

[1]  T. Casale,et al.  Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  M. Belvisi,et al.  Peroxisome proliferator-activated receptors as novel targets in lung disease. , 2008, Chest.

[3]  N. Thomson,et al.  Peroxisome proliferator‐activated receptor‐γ agonists as potential anti‐inflammatory agents in asthma and chronic obstructive pulmonary disease , 2006 .

[4]  So Ri Kim,et al.  Peroxisome proliferator activated receptor-γ modulates reactive oxygen species generation and activation of nuclear factor-κB and hypoxia-inducible factor 1α in allergic airway disease of mice , 2006 .

[5]  So Ri Kim,et al.  Involvement of IL-10 in Peroxisome Proliferator-Activated Receptor γ-Mediated Anti-Inflammatory Response in Asthma , 2005, Molecular Pharmacology.

[6]  D. Dombrowicz,et al.  Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. , 2004, The Journal of allergy and clinical immunology.

[7]  Y. Hashimoto,et al.  Improvement of asthma after administration of pioglitazone. , 2002, Diabetes care.

[8]  M. Aubier,et al.  Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. , 2001, American journal of respiratory and critical care medicine.

[9]  J. Hankinson,et al.  Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. , 2000, American journal of respiratory and critical care medicine.